News

Researchers at the University of Granada (UGR) and Virgen de las Nieves Hospital in Spain revealed that a brief exercise program, from 7 to 10 days, can improve quality of life and physical abilities while minimizing the need for hospitalization in patients with chronic obstructive pulmonary disease (COPD). The research article, “Results…

Aptar Pharma, a global provider of aerosols for healthcare and pharma products, unveiled its latest innovation — the eDose Counter for metered dose inhalers (MDIs) — at the Respiratory Drug Delivery (RDD) Scientific Conference April 17-21 in Phoenix, Arizona. The eDose Counters are engineered to improve treatment adherence in patients…

Propeller Health and AMC Health are partnering to assist patients with chronic obstructive pulmonary disease (COPD) and asthma manage their disease more efficiently and reduce symptoms, as well as hospital visits. The multi-year partnership was signed in January and will kick off this month with the launch of two…

A collaborative research study between several Australian institutions suggests that cigarette smoking and infection with viruses such as influenza can reduce the effectiveness of symptom-reliever drugs like salbutamol in patients with chronic obstructive pulmonary disease (COPD). These findings were published in a research article, “Influenza A virus…

Boehringer Ingelheim recently announced the publication of a new research article detailing the measurement of specific white blood cells, called eosinophils, to prediction the response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. The study was developed using data from the…

A research team discovered that innate lymphoid cells need certain nutrients to function, a finding that may lead to new treatments for patients with chronic obstructive pulmonary disease (COPD) and other inflammatory lung disorders. Researchers have long known that innate lymphoid cells play a vital role in promoting inflammatory reactions in the…

The U.S. Food and Drug Administration (FDA) recently approved a Supplemental New Drug Application (sNDA) for Boehringer Ingelheim Pharmaceuticals Inc.‘s Stiolto Respimat, adding data to the product’s labeling to reflect its demonstrated capacity to improve health-related quality of life in people with chronic obstructive pulmonary disease (COPD). Data came from Phase 3 clinical trials, OTEMTO…

The American Sleep Apnea Association (ASAA), a patient-led nonprofit organization to promote sleep health, has received approval from the Patient-Centered Outcomes Research Institute (PCORI)’s board of governors for a three-year, $2.5 million demonstration project into chronic obstructive pulmonary disease (COPD) and sleep apnea, called the O2VERLAP Study. The award for…

Boehringer Ingelheim Pharmaceuticals and Propeller Health are partnering to use digital health tools and services to help patients with asthma and chronic obstructive pulmonary disease (COPD) to better cope with their condition. Under the terms of the commercial agreement, people with asthma and COPD who are currently taking a Boehringer Ingelheim…

Verona Pharma, a clinical stage biopharmaceutical company focused on the development of therapeutic medicines to treat respiratory diseases, recently announced positive results of a Phase 2a dose-finding study on the new nebulized formulation of RPL554, its lead drug candidate. The positive data adds to the evidence that this drug could…